v3.26.1
Reportable Segment Information - Summary of Financial Information for Each Reportable Segment (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Sep. 30, 2025
Segment Reporting Information [Line Items]          
Sales $ 497 $ 463 $ 1,365 $ 1,347  
Cost of sales 327 331 943 957  
Selling, general and administrative expense 99 106 264 268  
Research and development expense 15 13 41 41  
Equity and other income 1 0 2 1  
Goodwill impairment and (income) loss on divestitures, net (1) 706 (3) 871  
Operating income (loss) 43 (708) 76 (836)  
Net interest and other (income) expense (8) (5) 19 34  
Other net periodic benefit (income) loss (5) 1 (3) 4  
Income (loss) from continuing operations before income taxes 56 (704) 60 (874)  
EBITDA [1] 90 (632) 217 (649)  
Depreciation expense 32 61 95 140  
Amortization expense 15 15 46 47  
Assets 4,578   4,578   $ 4,611
Property, plant and equipment, net 1,149   1,149   1,201
Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Selling, general and administrative expense 61 57 180 173  
Research and development expense 14 13 39 39  
Equity and other income 0 0 1 1  
Goodwill impairment and (income) loss on divestitures, net 0 706 0 706  
Operating income (loss) 80 (659) 158 (574)  
EBITDA [1] 126 (583) 298 (387)  
Depreciation expense 31 61 94 140  
Amortization expense 15 15 46 47  
Intersegment Eliminations [Member]          
Segment Reporting Information [Line Items]          
Sales [2] (11) (10) (29) (31)  
Cost of sales (11) (10) (29) (31)  
Life Sciences [Member]          
Segment Reporting Information [Line Items]          
Sales 180 162 491 468  
Assets 1,454   1,454   1,498
Property, plant and equipment, net 456   456   481
Life Sciences [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Sales 180 162 491 468  
Cost of sales 106 103 308 311  
Selling, general and administrative expense 20 18 61 58  
Research and development expense 4 4 11 12  
Equity and other income 0 0 0 0  
Goodwill impairment and (income) loss on divestitures, net 0 375 0 375  
Operating income (loss) 45 (343) 97 (301)  
EBITDA [1] 60 (321) 140 (240)  
Depreciation expense [3] 10 17 29 48  
Amortization expense 5 5 14 13  
Personal Care [Member]          
Segment Reporting Information [Line Items]          
Assets 705   705   751
Property, plant and equipment, net 100   100   101
Personal Care [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Sales 155 147 428 426  
Cost of sales 90 87 257 256  
Selling, general and administrative expense 22 21 63 62  
Research and development expense 6 6 17 19  
Equity and other income 0 0 1 1  
Goodwill impairment and (income) loss on divestitures, net 0 0 0 0  
Operating income (loss) 29 25 67 64  
EBITDA [1] 44 40 113 113  
Depreciation expense 7 7 21 23  
Amortization expense 8 8 25 26  
Specialty Additives [Member]          
Segment Reporting Information [Line Items]          
Sales 136 131 372 380  
Assets 964   964   1,020
Property, plant and equipment, net 462   462   484
Specialty Additives [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Sales 136 131 372 380  
Cost of sales 110 123 317 328  
Selling, general and administrative expense 17 17 50 49  
Research and development expense 4 3 10 8  
Equity and other income 0 0 0 0  
Goodwill impairment and (income) loss on divestitures, net 0 331 0 331  
Operating income (loss) 3 (345) (12) (343)  
EBITDA [1] 18 (309) 35 (276)  
Depreciation expense [4] 13 34 40 60  
Amortization expense 2 2 7 7  
Intermediates [Member]          
Segment Reporting Information [Line Items]          
Assets 107   107   116
Property, plant and equipment, net 30   30   30
Intermediates [Member] | Operating Segments [Member]          
Segment Reporting Information [Line Items]          
Sales 37 33 103 104  
Cost of sales 32 28 90 93  
Selling, general and administrative expense 2 1 6 4  
Research and development expense 0 0 1 0  
Equity and other income 0 0 0 0  
Goodwill impairment and (income) loss on divestitures, net 0 0 0 0  
Operating income (loss) 3 4 6 6  
EBITDA [1] 4 7 10 16  
Depreciation expense 1 3 4 9  
Amortization expense 0 0 0 1  
Unallocated and Other [Member]          
Segment Reporting Information [Line Items]          
Selling, general and administrative expense 38 49 84 95  
Research and development expense 1 0 2 2  
Equity and other income 1 0 1 0  
Goodwill impairment and (income) loss on divestitures, net (1) 0 (3) 165  
Operating income (loss) [5] (37) (49) (82) (262)  
EBITDA [1] (36) (49) (81) (262)  
Depreciation expense [6] 1 0 1 0  
Amortization expense 0 $ 0 0 $ 0  
Assets 1,348   1,348   1,226
Property, plant and equipment, net $ 101   $ 101   $ 105
[1] Excludes loss from discontinued operations, net of income taxes and other net periodic benefit (income) loss. See the Statements of Condensed Consolidated Comprehensive Income (Loss) for applicable amounts excluded.
[2] Intersegment sales from Intermediates are accounted for at prices that approximate market value. All other intersegment sales are accounted for at cost.
[3] Depreciation includes accelerated depreciation of $8 million and $21 million for Life Sciences for the three and nine months ended June 30, 2025, respectively.
[4] Depreciation includes accelerated depreciation of $1 million for Personal Care and $3 million for Specialty Additives for the nine months ended June 30, 2026, and $19 million for both the three and nine months ended June 30, 2025.
[5] Includes a $2 million excess land sale contract termination fee income for both the three and nine months ended June 30, 2026, a $8 million gain on sale and a $183 million impairment charge related to the Avoca business for both the nine months ended June 30, 2025, within the income (loss) on divestitures, net caption of the Statements of Condensed Consolidated Income (Loss).
[6] Depreciation includes accelerated depreciation of $1 million for Unallocated and other for both the three and nine months ended June 30, 2026.